Mallinckrodt's pain management portfolio contains the first and only IV formulation of acetaminophen in the U.S. for patients in need of an intravenous analgesic for the management of pain.
Our branded Intravenous Products portfolio includes:
OFIRMEV® (acetaminophen) injection 100 mL vials, 1000 mg (10 mg/mL)
INDICATIONS AND USAGE
OFIRMEV (acetaminophen) injection is indicated for the management of mild to moderate pain, management of moderate to severe pain with adjunctive opioid analgesics, and reduction of fever.
WARNING: RISK OF MEDICATION ERRORS AND HEPATOTOXICITY
Take care when prescribing, preparing, and administering OFIRMEV Injection to avoid dosing errors which could result in accidental overdose and death. In particular, be careful to ensure that:
OFIRMEV contains acetaminophen. Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed the recommended maximum daily limits, and often involve more than one acetaminophen-containing product.
Click “Learn More” for additional Important Risk Information including boxed warning and link to U.S. Full Prescribing Information. Learn More
Our diverse product portfolio and solid market positions reflect our more than 145-year history of pharmaceutical excellence with many innovations important for the treatment of pain.
Mallinckrodt, the 'M' brand mark, the Mallinckrodt Pharmaceuticals logo and other brands are trademarks of a Mallinckrodt company.
© 2017 Mallinckrodt. Mallinckrodt Pharmaceuticals is a registered business name of Mallinckrodt plc, which is registered in Ireland as a public limited company with registration number 522227 and has its registered office at College Business & Technology Park, Cruiserath, Blanchardstown, Dublin 15, Ireland.